Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPR3 | P17342 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753750 | 0.85 | ROCK2 (0.43) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL23318499 | 0.83 | ROCK2 (0.42) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL26549546 | 0.80 | ROCK2 (0.40) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL1753582 | 0.78 | MEN1 (0.54) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL19901428 | 0.78 | MEN1 (0.54) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL27305897 | 0.78 | ELANE (0.52) | KMT2AMEN1L3MBTL1SMN1; SMN2ELANE | |
| SCHEMBL18792766 | 0.77 | ELANE (0.46) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL23051176 | 0.77 | ROCK2 (0.42) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL24541057 | 0.76 | MEN1 (0.43) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL23420957 | 0.76 | KMT2A (0.43) | ROCK2KMT2AMEN1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-10653794-B2 | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation | PFIZER INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190030183-A1 | CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION | PFIZER INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | NOVARTIS AG (CH) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ROCK2 4010/4885KMT2A 1026/4885MEN1 1237/4885 |
| US-10653794-B2 | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation | GCLC, LANCL1, CTH | ROCK2 2449/4885KMT2A 2033/4885MEN1 4028/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ROCK2 4010/4885KMT2A 1026/4885MEN1 1237/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | ROCK2 3857/4885KMT2A 1003/4885MEN1 1247/4885 |
| US-20190030183-A1 | CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION | GCLC, LANCL1, CTH | ROCK2 2449/4885KMT2A 2033/4885MEN1 4028/4885 |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | ROCK2 4465/4885KMT2A 1050/4885MEN1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.